# Treatment options for acute myeloid leukemia
Treatment of acute myeloid leukemia (AML) depends heavily on individual circumstances: age, overall health, genetic characteristics of leukemia cells, and whether this is an initial diagnosis or disease recurrence. Most treatments aim to eliminate abnormal blood cells and restore normal blood production. Below are the main treatment forms described by category.
Intensive chemotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Intensive chemotherapy (induction chemotherapy) has been the standard treatment for many patients for decades, especially those young enough and without contraindications. The classic combination consists of an anthracycline (for example daunorubicin) and cytarabine, administered in short, intensive cycles.
The method is that these drugs damage the DNA of rapidly dividing cells, causing leukemic cells to die. However, they also affect healthy cells, especially in the bone marrow, leading to serious side effects. Many patients undergo intensive chemotherapy in the hospital, because they require extensive medical support: blood transfusions, antibiotics against infections (because the immune system is temporarily severely weakened) and treatment of bleeding problems. Other common side effects are nausea, vomiting, headache, mucositis and fatigue.
Hypomethylating agents
ProveniIncluded in official guidelines, or approved by EMA or FDA
Hypomethylating agents such as azacitidine and decitabine are prescribed especially to elderly patients or those who cannot tolerate intensive chemotherapy. They work at a different level: they influence the way genes are 'turned off' (methylation) in leukemic cells, allowing normal gene function to be restored.
These drugs are often administered on an outpatient basis (not in the hospital) and generally cause fewer acute side effects than intensive chemotherapy. Common side effects include fatigue, low blood cell counts (which can cause infections, anemia and bleeding) and mild gastrointestinal complaints.
Venetoclax in combination
ProveniIncluded in official guidelines, or approved by EMA or FDA
The combination of venetoclax (a BCL2 inhibitor) with hypomethylating agents or low-dose cytarabine has been standard treatment for many elderly patients not eligible for intensive chemotherapy in recent years. Venetoclax activates a specific form of cell death in leukemic cells that overproduce certain proteins.
This combination can be given both in the hospital and on an outpatient basis. Side effects include infections, fatigue, anemia and bleeding tendency. Because venetoclax interacts with many other drugs, interactions must be carefully monitored.
Treatment targeting specific mutations
ProveniIncluded in official guidelines, or approved by EMA or FDA
(FLT3 inhibitors, IDH inhibitors)
When leukemic cells have certain genetic abnormalities, targeted drugs can help. Examples include:
- **FLT3 inhibitors** (e.g. midostaurin): work in patients with FLT3-mutated AML by disabling a specific protein that keeps leukemic cells alive.
- **IDH inhibitors** (e.g. ivosidenib, enasidenib): target IDH1 or IDH2 mutations, which occur in some AMLs. They restore normal cell differentiation.
These drugs are usually given in combination with other chemotherapies. Side effects vary, but may include differentiation syndrome (sudden involvement of lungs and kidneys), fatigue and liver abnormalities.
Stem Cell Transplantation
ProveniIncluded in official guidelines, or approved by EMA or FDA
Allogeneic hematopoietic stem cell transplantation (SCT) is a form of treatment in which healthy stem cells from a donor (related or unrelated) are implanted after destroying the patient's bone marrow with high-dose chemotherapy or radiation. This gives the donor's immune system a chance to attack remaining leukemic cells (graft-versus-leukemia effect).
This treatment is intensive and carries significant risks: infections, graft-versus-host disease (damage to normal tissues by donor immune cells), organ failure, and prolonged hospitalization. It is usually reserved for patients in first remission with unfavorable genetic features, or for patients with disease recurrence. Preparation (conditioning) is sometimes done with low-dose (less intensive) regimens in elderly patients.
Venetoclax-free regimens and other combinations
ResearchediPositive results in clinical studies, not yet standard treatment
Studies are underway into alternative combinations without venetoclax, especially because this drug is not suitable for all patients. Other agents such as vorinostat (a histone deacetylase inhibitor) are also being investigated, sometimes in combination with azacitidine.
These regimens are still in clinical trials, but initial results suggest usefulness for certain patient groups.
Venetoclax: different treatment durations
ResearchediPositive results in clinical studies, not yet standard treatment
How many months patients should continue using venetoclax (for example, 2 years versus longer) is a subject of research. The questions are how long treatment remains effective and when the risk of side effects outweighs the benefits.
CDK8 inhibitors and other molecular targets
ExperimentaliOngoing in study setting, outcome still unknown
Recent research focuses on inhibiting specific proteins that help leukemic cells grow, such as CDK8. These approaches are still in early stages and are not available outside clinical studies.
CAR-T-cell therapy
ExperimentaliOngoing in study setting, outcome still unknown
This is a form of immunotherapy in which T cells from the patient are genetically modified to recognize and attack leukemic cells. This is being investigated in clinical trials for AML. Various forms of CAR-T therapy have already been approved for certain lymphoblastic leukemias, but for AML we are still in the experimental phase.
Possible side effects include cytokine release syndrome (severe inflammatory reaction) and neurological complications.
Supportive care
ProveniIncluded in official guidelines, or approved by EMA or FDA
Supportive care is essential and forms an integral part of treatment. This includes:
- **Blood transfusions** for anemia and clotting problems
- **Antibiotics and antiviral agents** for prevention and treatment of infections
- **Antifungal treatment** against fungal infections
- **Hospitalization and monitoring** during infectious periods
- **Psychological and social support**
Without this support, chemotherapies and other treatments cannot be safely administered.
Observation and watchful waiting
ProveniIncluded in official guidelines, or approved by EMA or FDA
In some patients, especially those with certain genetic characteristics or very limited symptoms, observation may initially be chosen instead of immediate treatment. This is not always experienced as 'inactivity' — it involves regular check-ups. Once the disease progresses, treatment is started.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._